PLASMA Act

Bill 118 hr 6465, also known as the PLASMA Act, is a piece of legislation introduced in the US Congress that aims to address the shortage of plasma, a crucial component in the production of life-saving medications. The bill seeks to increase the availability of plasma by incentivizing individuals to donate plasma through a tax credit program.

Under the PLASMA Act, individuals who donate plasma would be eligible for a tax credit of up to $200 per year. This tax credit is intended to encourage more people to donate plasma, which is used in the treatment of a variety of medical conditions, including immune deficiencies, hemophilia, and certain neurological disorders.

The bill also includes provisions to streamline the process of plasma donation and ensure the safety and quality of donated plasma. This includes requirements for plasma collection centers to adhere to strict guidelines set by the Food and Drug Administration (FDA) and other regulatory bodies. Overall, the PLASMA Act is aimed at increasing the supply of plasma in order to meet the growing demand for plasma-derived medications. By incentivizing individuals to donate plasma and implementing measures to ensure the safety and quality of donated plasma, the bill seeks to address the shortage of this vital medical resource.